Biomaterial Database

Botulinum A toxin for glabellar wrinkles. Dose and response. 1998

C L Hankins, and R Strimling, and G S Rogers

Department of Surgery, Boston University School of Medicine, Massachusetts 02118, USA.

BACKGROUND Botulinum A exotoxin injection is a well-established method for treatment of glabellar frown lines, crow's feet, and horizontal furrows of the forehead. However, there is no consensus as to the optimal dosage per injection site or the concentration of injectate to be used. OBJECTIVE The purpose of this study was to determine the minimal effective dose per injection site to be used as well as the effect of concentration in response to treatment. RESULTS A total of 46 subjects were divided into ten groups and injected with escalating doses and concentrations of botulinum toxin. The response and longevity of treatment were then followed on a monthly basis. A dose between 2.5-4 U per injection site (12.5-20 U total) was determined to be an effective starting dose, with a duration of 2-5 months (median 14 weeks). CONCLUSIONS There was no statistically significant difference in safety or efficacy for concentrations ranging from 50 to 200 U/ml of botulinum toxin.

UI	MeSH Term	Description	Entries
D007928	Lethal Dose 50	The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.	LD50,Dose 50, Lethal
D009121	Muscle Denervation	The resection or removal of the innervation of a muscle or muscle tissue.	Denervation, Muscle,Denervations, Muscle,Muscle Denervations
D009465	Neuromuscular Agents	Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.	Skeletal Muscle Relaxants,Neuromuscular Effect,Neuromuscular Effects,Agents, Neuromuscular,Effect, Neuromuscular,Effects, Neuromuscular,Muscle Relaxants, Skeletal,Relaxants, Skeletal Muscle
D004305	Dose-Response Relationship, Drug	The relationship between the dose of an administered drug and the response of the organism to the drug.	Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005152	Facial Muscles	Muscles of facial expression or mimetic muscles that include the numerous muscles supplied by the facial nerve that are attached to and move the skin of the face. (From Stedman, 25th ed)	Mimetic Muscles,Facial Muscle,Mimetic Muscle,Muscle, Facial,Muscle, Mimetic,Muscles, Facial,Muscles, Mimetic
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D012449	Safety	Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.	Safeties
D015595	Skin Aging	The process of aging due to changes in the structure and elasticity of the skin over time. It may be a part of physiological aging or it may be due to the effects of ultraviolet radiation, usually through exposure to sunlight.	Photoaging of Skin,Skin Wrinkling,Solar Aging of Skin,Aging, Skin,Skin Wrinklings,Wrinkling, Skin

Related Publications

C L Hankins, and R Strimling, and G S Rogers

Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study.

September 2002, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],

C L Hankins, and R Strimling, and G S Rogers

Botulinum toxins for facial wrinkles: beyond glabellar lines.

February 2007, Facial plastic surgery clinics of North America,

C L Hankins, and R Strimling, and G S Rogers

Patient selection in the treatment of glabellar wrinkles with botulinum toxin type A injection.

March 1997, Archives of otolaryngology--head & neck surgery,

C L Hankins, and R Strimling, and G S Rogers

Supraciliary wrinkles and botulinum toxin A.

June 2010, Clinical and experimental dermatology,

C L Hankins, and R Strimling, and G S Rogers

Botulinum toxin type A for facial wrinkles.

July 2021, The Cochrane database of systematic reviews,

C L Hankins, and R Strimling, and G S Rogers

[Skin, wrinkles and botulinum toxin].

July 2003, Annales de readaptation et de medecine physique : revue scientifique de la Societe francaise de reeducation fonctionnelle de readaptation et de medecine physique,

C L Hankins, and R Strimling, and G S Rogers

Botulinum toxin injection for facial wrinkles.

August 2014, American family physician,

C L Hankins, and R Strimling, and G S Rogers

Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A.

May 2003, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],

C L Hankins, and R Strimling, and G S Rogers

[GLABELLAR WRINKLES].

August 1963, La Semana medica,

C L Hankins, and R Strimling, and G S Rogers

Nerve Block Guided by Anatomic Landmarks Only Reduces Pain in Botulinum Toxin Type A Treatment for Glabellar and Forehead Wrinkles.

May 2024, Annals of plastic surgery,